Small molecule inhibitors of BRAF in clinical trials

  • Bioorg Med Chem Lett. 2012 Jan 15;22(2):789-92. doi: 10.1016/j.bmcl.2011.11.060.
Alfonso Zambon  1 ,  Ion Niculescu-Duvaz ,  Dan Niculescu-Duvaz ,  Richard Marais ,  Caroline J Springer
Affiliations
  • 1. The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.
PMID: 22222036 DOI: 10.1016/j.bmcl.2011.11.060
Abstract

Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.